MA31779B1 - Activateurs de glucokinase - Google Patents

Activateurs de glucokinase

Info

Publication number
MA31779B1
MA31779B1 MA32775A MA32775A MA31779B1 MA 31779 B1 MA31779 B1 MA 31779B1 MA 32775 A MA32775 A MA 32775A MA 32775 A MA32775 A MA 32775A MA 31779 B1 MA31779 B1 MA 31779B1
Authority
MA
Morocco
Prior art keywords
glucokinase
glucokinase activators
gily
glycemia
affection
Prior art date
Application number
MA32775A
Other languages
Arabic (ar)
English (en)
Inventor
Thomas Daniel Aicher
Steven Armen Boyd
Mark Joseph Chicarelli
Kevin Ronald Condroski
Jay Bradford Fell
John P Fischer
Indrani W Gunawardana
Ronald Jay Hinklin
Ajay Singh
Timothy M Turner
Eli M Wallace
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of MA31779B1 publication Critical patent/MA31779B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)

Abstract

CETTE INVENTION CONCERNE DES COMPOSÉS DE FORMULE I OÙ R2, R3, R13, L ET D2 SONT TELS QUE DÉFINIS DANS LA DESCRIPTION, QUI SONT UTILISÉS DANS LE TRAITEMENT ET/OU LA PRÉVENTION DES MALADIES OU DES AFFECTIONS ASSOCIÉES AVEC DES TAUX DÉFICITAIRES DE L'ACTIVITÉ GLUCOKINASE, OU QUI PEUVENT ÊTRE TRAITÉES PAR ACTIVATION DE LA GLUCOKINASE Y COMPRIS, MAIS SANS Y ÊTRE LIMITÉS, LE DIABÈTE SUCRÉ, L'INTOLÉRANCE AU GLUCOSE, L'HYPERGLYCÉMIE MODÉRÉE À JEUN, LA GLYCÉMIE À JEUN ANORMALE, ET TOUTE AUTRE MALADIE ET AFFECTION COMME CELLES ÉVOQUÉES ICI.
MA32775A 2007-09-21 2010-04-14 Activateurs de glucokinase MA31779B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97422507P 2007-09-21 2007-09-21
PCT/US2008/076401 WO2009042435A1 (fr) 2007-09-21 2008-09-15 Activateurs de glucokinase

Publications (1)

Publication Number Publication Date
MA31779B1 true MA31779B1 (fr) 2010-10-01

Family

ID=40250949

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32775A MA31779B1 (fr) 2007-09-21 2010-04-14 Activateurs de glucokinase

Country Status (28)

Country Link
US (3) US8212045B2 (fr)
EP (4) EP2573087A1 (fr)
JP (1) JP5722037B2 (fr)
KR (1) KR101566042B1 (fr)
CN (1) CN101868459B (fr)
AR (1) AR068628A1 (fr)
AU (1) AU2008305294B2 (fr)
BR (1) BRPI0816881A2 (fr)
CA (1) CA2699718C (fr)
CO (1) CO6270223A2 (fr)
CR (2) CR11383A (fr)
DK (1) DK2209778T3 (fr)
EA (1) EA019104B1 (fr)
ES (2) ES2569734T3 (fr)
HR (1) HRP20120814T1 (fr)
IL (1) IL204264A (fr)
MA (1) MA31779B1 (fr)
MX (1) MX2010002772A (fr)
MY (1) MY180558A (fr)
NZ (1) NZ583538A (fr)
PL (1) PL2209778T3 (fr)
PT (1) PT2209778E (fr)
SI (1) SI2209778T1 (fr)
TN (1) TN2010000100A1 (fr)
TW (1) TWI423799B (fr)
UA (1) UA101166C2 (fr)
WO (1) WO2009042435A1 (fr)
ZA (2) ZA201002206B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2669687C (fr) * 2006-11-15 2013-09-10 Forest Laboratories Holdings Limited Derives de phtalazine
EP2573087A1 (fr) 2007-09-21 2013-03-27 Array Biopharma, Inc. Dérivés pyridin-2-yl-amino-1,2,4-thiadiazole en tant qu'activateurs de la glucoquinase pour le traitement de diabetes mellitus
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
CN102959076B (zh) 2010-03-31 2015-09-16 斯克里普斯研究所 重编程细胞
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
JP2013536233A (ja) 2010-08-23 2013-09-19 アムジエン・インコーポレーテツド グルコキナーゼ調節タンパク質と相互作用する糖尿病治療用の化合物
JPWO2012121314A1 (ja) 2011-03-09 2014-07-17 第一三共株式会社 ジピリジルアミン誘導体
CN103717586A (zh) 2011-04-05 2014-04-09 安姆根有限公司 用于治疗糖尿病的与葡糖激酶调节蛋白相互作用的苯并二氧杂*和苯并二氧杂环己烯化合物
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
WO2013045413A1 (fr) 2011-09-27 2013-04-04 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
CN104230892B (zh) * 2011-11-09 2016-12-07 福建海西新药创制有限公司 一组提高激酶活性的化合物及其应用
WO2013123444A1 (fr) 2012-02-17 2013-08-22 Amgen Inc. Composés de sulfonyle qui interagissent avec la protéine régulatrice de la glucokinase
WO2013173382A1 (fr) 2012-05-15 2013-11-21 Amgen Inc. Benzothiophène sulfonamides et autres composés qui interagissent avec une protéine régulatrice de la glucokinase
CA2877026A1 (fr) 2012-05-18 2013-11-21 Amgen Inc. Procede pour la preparation de thiadiazoles
EP2917213A1 (fr) * 2012-11-09 2015-09-16 Array Biopharma, Inc. Formes cristallines de (1s)-1-[5-({3-[(2-méthylpyridin-3-yl)oxy]-5-(pyridin-2-ylsulfanyl)pyridin-2-yl}amino)-1,2,4-thiadiazol-3-yl]éthane-1,2-diol
WO2016059647A2 (fr) * 2014-10-13 2016-04-21 SHRI CHHATRAPTI SHIVAJI COLLEGE Maharashtra, India) Dérivés de triaminotriazine et de picolinonitrile utilisables en tant qu'inhibiteurs efficaces de la transcriptase inverse du vih-1
GB201714777D0 (en) 2017-09-14 2017-11-01 Univ London Queen Mary Agent
SG11202003879RA (en) 2017-10-30 2020-05-28 Neuropore Therapies Inc Substituted phenyl sulfonyl phenyl triazole thiones and uses thereof
AU2019278015B2 (en) * 2018-05-31 2024-10-03 Hua Medicine (Shanghai) Ltd. Pharmaceutical combination, composition, and combination formulation comprising glucokinase activator and SGLT-2 inhibitor and preparation methods and uses thereof

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3983246A (en) 1974-04-04 1976-09-28 Fmc Corporation N-(sulfonyloxy) benzimidoyl halides as bactericidal or fungicidal agents
DE2949913A1 (de) * 1979-12-12 1981-06-25 Basf Ag, 6700 Ludwigshafen Azofarbstoffe
EP0300688A1 (fr) 1987-07-21 1989-01-25 FISONS plc Dérivés de pyrrole, procédé de préparation et compositions pharmaceutiques les contenant
JPH0228168A (ja) * 1988-04-14 1990-01-30 Sankyo Co Ltd チアゾール誘導体
US5326776A (en) * 1992-03-02 1994-07-05 Abbott Laboratories Angiotensin II receptor antagonists
WO1993024442A1 (fr) 1992-05-29 1993-12-09 Yamanouchi Pharmaceutical Co., Ltd. Medicament renfermant un derive d'acide benzoique, et nouveau derive d'acide benzoique
CA2193725A1 (fr) 1994-06-24 1996-01-04 David Cavalla Composes derives d'aryles et utilisation de ces composes comme inhibiteurs de l'activite de la phosphodiesterase iv
GB9908410D0 (en) * 1999-04-13 1999-06-09 Pfizer Ltd Pyridines
EP1169038B9 (fr) * 1999-04-15 2013-07-10 Bristol-Myers Squibb Company Inhibiteurs cycliques de proteine tyrosine kinase
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
YU72201A (sh) 1999-04-28 2005-07-19 Aventis Pharma Deutschland Gmbh. Derivati di-aril kiseline kao ppar receptorski ligandi
WO2000076984A2 (fr) 1999-05-21 2000-12-21 Biovitrum Ab Nouveaux composes, et utilisation et preparation de ces derniers
US6465467B1 (en) * 1999-05-21 2002-10-15 Biovitrum Ab Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases
JP4144978B2 (ja) 1999-09-09 2008-09-03 富士フイルム株式会社 １，２，４−チアジアゾール誘導体の合成法
AU779908B2 (en) 1999-09-10 2005-02-17 Merck & Co., Inc. Tyrosine kinase inhibitors
US6906067B2 (en) * 1999-12-28 2005-06-14 Bristol-Myers Squibb Company N-heterocyclic inhibitors of TNF-α expression
US20020065270A1 (en) 1999-12-28 2002-05-30 Moriarty Kevin Joseph N-heterocyclic inhibitors of TNF-alpha expression
EP1246823A1 (fr) 1999-12-28 2002-10-09 Pharmacopeia, Inc. Composes de pyrimidine et de triazine presentant une activite inhibant la kinase
US7345051B2 (en) 2000-01-31 2008-03-18 Genaera Corporation Mucin synthesis inhibitors
NZ523656A (en) 2000-08-31 2004-11-26 Pfizer Prod Inc Pyrazole derivatives and their use as protein kinase inhibitors
US20050209297A1 (en) * 2000-08-31 2005-09-22 Pfizer Inc Pyrazole derivatives
US20020132836A1 (en) 2000-10-11 2002-09-19 Chemocentryx Inc. Compounds and methods for modulating CCR4 function
AU2002213467A8 (en) 2000-10-11 2009-07-30 Chemocentryx Inc Modulation of ccr4 function
CN1486302A (zh) 2000-12-07 2004-03-31 CV���ƹ�˾ 作为抗冠状动脉疾病或动脉硬化的abca-1加强化合物的取代1,3,5-三嗪和嘧啶
US6989385B2 (en) 2000-12-21 2006-01-24 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
AU2002258400A1 (en) 2001-02-16 2002-08-28 Tularik Inc. Methods of using pyrimidine-based antiviral agents
US7144903B2 (en) * 2001-05-23 2006-12-05 Amgen Inc. CCR4 antagonists
PE20030008A1 (es) 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
CA2450934A1 (fr) 2001-06-19 2002-12-27 Marco Dodier Inhibiteurs pyrimidine de la phosphodiesterase (pde) 7
CA2450562A1 (fr) * 2001-06-22 2003-01-03 Merck & Co., Inc. Inhibiteurs de tyrosine kinase
JP4505228B2 (ja) 2002-01-10 2010-07-21 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト Ｒｈｏ−キナーゼ阻害剤
KR100875362B1 (ko) 2002-02-05 2008-12-22 아스텔라스세이야쿠 가부시키가이샤 2,4,6-트리아미노-1,3,5-트리아진 유도체
US6846928B2 (en) * 2002-03-15 2005-01-25 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
DE60332433D1 (de) * 2002-03-15 2010-06-17 Vertex Pharma Azolylaminoazine als proteinkinasehemmer
US20040009981A1 (en) * 2002-03-15 2004-01-15 David Bebbington Compositions useful as inhibitors of protein kinases
EP1485381B8 (fr) * 2002-03-15 2010-05-12 Vertex Pharmaceuticals Incorporated Azolylaminoazines en tant qu'inhibiteurs de proteines kinases
US8299108B2 (en) * 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
WO2003082272A1 (fr) 2002-03-29 2003-10-09 Chiron Corporation Benzazoles substitues et leur utilisation en tant qu'inhibiteurs de la kinase raf
WO2003091213A1 (fr) * 2002-04-25 2003-11-06 Yamanouchi Pharmaceutical Co., Ltd. Derives d'amide ou sels de ces derives
AU2003249369A1 (en) 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain amino-substituted monocycles as kinase modulators
TW200424183A (en) 2002-08-09 2004-11-16 Nps Pharma Inc New compounds
BR0314196A (pt) 2002-09-10 2005-07-26 Scios Inc Inibidores de tgf-beta
BR0314864A (pt) 2002-10-03 2005-08-02 Novartis Ag Compostos orgânicos
CA2503715A1 (fr) 2002-10-30 2004-05-21 Merck & Co., Inc. Inhibiteurs de kinase
RU2351590C2 (ru) 2003-02-10 2009-04-10 Вертекс Фармасьютикалз Инкорпорейтед Способ получения диариламина
EP1594512A4 (fr) 2003-02-11 2007-07-11 Kemia Inc Composes destines au traitement d'une infection virale
NZ540791A (en) 2003-02-13 2009-09-25 Banyu Pharma Co Ltd Novel 2-pyridinecarboxamide derivatives
JP2006522125A (ja) 2003-03-25 2006-09-28 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼのインヒビターとして有用なチアゾール
US7244763B2 (en) * 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
JP2007504229A (ja) 2003-09-02 2007-03-01 メルク　エンド　カムパニー　インコーポレーテッド 代謝調節型グルタミン酸受容体−５のモジュレーターとしてのビピリジルアミン類およびエーテル類
US7470712B2 (en) 2004-01-21 2008-12-30 Bristol-Myers Squibb Company Amino-benzazoles as P2Y1 receptor inhibitors
WO2005077373A2 (fr) 2004-02-03 2005-08-25 Astrazeneca Ab Nouveau traitement du reflux gastro-oesophagien pathologique ii
AR049418A1 (es) 2004-02-27 2006-08-02 Bayer Pharmaceuticals Corp Derivados de heteroarilaminopirazol y composiciones farmaceuticas para el tratamiento de la diabetes.
KR20050091462A (ko) 2004-03-12 2005-09-15 한국과학기술연구원 푸로피리미딘 화합물 및 이를 포함하는 ｄｄｒ2 티로신키나아제 활성 저해제
US7687502B2 (en) 2004-03-23 2010-03-30 Banyu Pharmaceutical Co., Ltd. Substituted quinazoline or pyridopyrimidine derivative
US7781451B2 (en) * 2004-04-02 2010-08-24 Novartis Ag Thiazolopyridine derivatives, pharmaceut ical conditions containing them and methods of treating glucokinase mediated conditions
AU2005233642A1 (en) 2004-04-13 2005-10-27 Astellas Pharma Inc. Polycyclic pyridines as potassium ion channel modulators
CA2561831A1 (fr) 2004-04-13 2005-12-22 Icagen, Inc. Pyrazines polycycliques tenant lieu de modulateurs du canal ionique du potassium
TW200606129A (en) * 2004-07-26 2006-02-16 Chugai Pharmaceutical Co Ltd Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
KR20060079121A (ko) 2004-12-31 2006-07-05 에스케이케미칼주식회사 당뇨 및 비만 치료예방에 유효한 퀴나졸린 유도체
WO2006078621A2 (fr) 2005-01-19 2006-07-27 Bristol-Myers Squibb Company Composes heteroaryle tenant lieu d'inhibiteurs du recepteur p2y1
DE102005025161A1 (de) 2005-06-01 2006-12-07 Phenion Gmbh & Co. Kg Derivate des Pyrimidins und Triazins und deren Verwendung
ATE542814T1 (de) * 2005-08-18 2012-02-15 Vertex Pharma Pyrazinkinaseinhibitoren
WO2007026761A1 (fr) * 2005-08-31 2007-03-08 Astellas Pharma Inc. Dérivé de thiazole
WO2007038387A2 (fr) 2005-09-23 2007-04-05 Yale University Composes et methodes de traitement des virus et du cancer
NZ567858A (en) * 2005-11-01 2011-08-26 Array Biopharma Inc Pyridine compounds useful as Glucokinase activators
MX2008005814A (es) 2005-11-03 2008-10-15 Vertex Pharma Aminopirimidinas utiles como inhibidores de cinasa.
US20070179125A1 (en) * 2005-11-16 2007-08-02 Damien Fraysse Aminopyrimidines useful as kinase inhibitors
WO2007058482A1 (fr) 2005-11-16 2007-05-24 Lg Life Sciences, Ltd. Inhibiteurs de la proteine kinase
CN101437512A (zh) * 2006-01-27 2009-05-20 阿雷生物药品公司 葡萄糖激酶活化剂
RU2457207C2 (ru) * 2006-03-24 2012-07-27 Эррэй Биофарма Инк. Активаторы глюкокиназы
ES2352320T3 (es) * 2006-05-12 2011-02-17 Ab Science Nuevo procedimiento para la síntesis de compuestos de 2-aminoxazol.
WO2008024963A1 (fr) 2006-08-24 2008-02-28 Serenex, Inc. Dérivés de benzène, de pyridine et de pyridazine
TW200825060A (en) 2006-10-26 2008-06-16 Astrazeneca Ab Chemical compounds
EA017405B9 (ru) 2006-12-08 2014-05-30 АйАрЭм ЭлЭлСи Соединения и композиции в качестве ингибиторов протеинкиназы
WO2008091770A1 (fr) 2007-01-24 2008-07-31 Array Biopharma Inc. Dérivés de 2-aminopyridine utilisés comme activateurs de la glucokinase
CA2681695A1 (fr) * 2007-03-23 2008-10-02 Array Biopharma Inc. Analogues de la 2-aminopyridine comme activateurs de la glucokinase
US7776857B2 (en) 2007-04-05 2010-08-17 Amgen Inc. Aurora kinase modulators and method of use
US20090012091A1 (en) 2007-07-02 2009-01-08 Kinagen, Inc. Oximide derivatives and their therapeutical application
WO2009022171A1 (fr) 2007-08-13 2009-02-19 Astrazeneca Ab Composés chimiques 1 - 821
EP2573087A1 (fr) 2007-09-21 2013-03-27 Array Biopharma, Inc. Dérivés pyridin-2-yl-amino-1,2,4-thiadiazole en tant qu'activateurs de la glucoquinase pour le traitement de diabetes mellitus
BRPI0818658A2 (pt) 2007-10-09 2015-04-14 Merck Patent Ges Mit Beschränkter Haftung Derivados de piridina úteis como ativadores de glicoquinase

Also Published As

Publication number Publication date
TN2010000100A1 (en) 2011-09-26
ES2569734T3 (es) 2016-05-12
TWI423799B (zh) 2014-01-21
HK1145498A1 (en) 2011-04-21
CR11383A (es) 2010-08-13
TW200914007A (en) 2009-04-01
IL204264A (en) 2015-06-30
KR20100080809A (ko) 2010-07-12
ZA201002206B (en) 2011-06-29
EP2209778B1 (fr) 2012-08-29
CN101868459A (zh) 2010-10-20
US8853409B2 (en) 2014-10-07
CA2699718C (fr) 2014-05-27
EP2727910B1 (fr) 2016-03-16
WO2009042435A1 (fr) 2009-04-02
US9079890B2 (en) 2015-07-14
US20100204240A1 (en) 2010-08-12
CN101868459B (zh) 2013-12-18
CO6270223A2 (es) 2011-04-20
PL2209778T3 (pl) 2013-02-28
NZ583538A (en) 2012-06-29
AR068628A1 (es) 2009-11-25
HRP20120814T1 (hr) 2012-11-30
JP5722037B2 (ja) 2015-05-20
DK2209778T3 (da) 2012-09-17
EA201000515A1 (ru) 2010-10-29
EP2209778A1 (fr) 2010-07-28
ES2393824T3 (es) 2012-12-28
WO2009042435A8 (fr) 2009-10-08
PT2209778E (pt) 2012-12-06
UA101166C2 (ru) 2013-03-11
BRPI0816881A2 (pt) 2015-03-17
ZA201102350B (en) 2012-09-26
US8212045B2 (en) 2012-07-03
CR20150131A (es) 2015-04-30
EP3078662A1 (fr) 2016-10-12
SI2209778T1 (sl) 2012-12-31
EA019104B1 (ru) 2014-01-30
MY180558A (en) 2020-12-02
CA2699718A1 (fr) 2009-04-02
AU2008305294A1 (en) 2009-04-02
HK1197821A1 (en) 2015-02-18
EP2573087A1 (fr) 2013-03-27
US20120277242A1 (en) 2012-11-01
EP2727910A1 (fr) 2014-05-07
AU2008305294B2 (en) 2012-11-29
KR101566042B1 (ko) 2015-11-04
US20150057448A1 (en) 2015-02-26
MX2010002772A (es) 2010-03-31
JP2010540443A (ja) 2010-12-24

Similar Documents

Publication Publication Date Title
MA31779B1 (fr) Activateurs de glucokinase
MA33606B1 (fr) Dérivés de pyrimidine en tant qu'inhibiteurs de protéine tyrosine kinase 2
MA28681B1 (fr) 3-aminocyclopentanecarboxamides utiles comme modulateurs de récepteurs de chimiokines
MX2007004882A (es) Derivados de xantina con actividad de receptor de hm74a.
MA29693B1 (fr) Derives de xanthine en tant qu'agonistes hm74a selectifs
MA30274B1 (fr) Composes organiques
WO2005077950A3 (fr) Composes
WO2006084176A3 (fr) Composes et compositions utilises comme modulateurs de ppar
MY140187A (en) Novel tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
MA27156A1 (fr) NUCLEOSIDES 3- β-D-RIBOFURANOSYLTHIAZOLO[4,5-d] PYRIDIMINE ET LES UTILISATIONS DE CELLES-CI
MA31158B1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes
WO2008011476A3 (fr) Compositions et procédés destinés à moduler l'activité de la sirtuine
EA200602191A1 (ru) 5,5-дизамещённые-2-амино-4-тиазолидиноны и способ их получения, фармацевтическая композиция и способ лечения
ATE329596T1 (de) Phthalazinderivate zur behandlung von entzündlicher erkrankungen
HRP20040684A2 (hr) Spojevi 2,4-pirimidindiamina i njihova upotreba
MA28680B1 (fr) 3-aminocyclopentanecarboxamides utiles comme modulateurs de récepteurs de chimiokines
DE602005024004D1 (de) Als beta-sekretase (bace)-hemmer nützliche 2-amino-chinazolinderivate
MA33155B1 (fr) Composes organiques et leurs utilisations
WO2007100366A3 (fr) Modulateurs allostériques positifs du récepteur de la quinolone m1
MA30089B1 (fr) (arylsulfonyl)-pyrasolopiperidines
MA32282B1 (fr) Dérivés de 2-phényl-pyridine substitués
EP1543158A4 (fr) Compositions th rapeutiques aptam riques r gul es
MA28038A1 (fr) Thienopyrazoles
TW200505880A (en) Diarylcycloalkyl derivatives, process for their preparation and their use as pharmaceuticals
NO20090205L (no) Cykliske derivater som modulatorer av kjemokin reseptor aktiviteten